Abstract
Introduction

61
Cardiovascular diseases (CVD) remain the leading cause of mortality in modern 62 societies and advancing age is the primary risk factor for CVD (26) . With the rapidly changing 63 demographics of aging and record numbers of older adults, the burden of disease is projected 64 to increase to unprecedented levels in the near future (14). As such, it is of upmost importance 65 to establish evidence-based interventions to prevent or delay the development and progression 66 of CVD.
67
As much as 80% of all CVD are associated with dysfunction and disorders of arteries,
68
namely stiffening of the large elastic arteries and vascular endothelial dysfunction (24, 26).
69
Several mechanisms are responsible for these changes, with reductions in the bioavailability of 70 the vascular-protective molecule, nitric oxide (NO) being among the most important (7, 33, 34).
71
The nitrite anion (inorganic nitrite), once considered an inert byproduct of NO metabolism, is 72 now recognized as a cytoprotective molecule and the major storage form of NO in tissues.
73
Through a one-step reduction to NO, nitrite augments circulating and tissue NO bioavailability 
97
Materials and Methods
98
This double-blind, placebo-controlled, randomized parallel-design study was conducted 
117
To increase the generalizability of the study, some subjects were enrolled even if they took 
129
All procedures were approved by the Institutional Review Board at the University of for 10 weeks. Subjects were educated by a CTRC registered dietician about foods containing 140 moderate and high levels of nitrate or nitrite (e.g., spinach, kale, beets), and subjects were 141 instructed to maintain a constant dietary intake of these foods and to avoid beets and beetroot 142 juice throughout the study. Sample size was estimated using an effect size of 0.74 from 143 published data in humans assessing the effects of oral nitrates on blood pressure (21, 36, 44),
144
brachial artery flow-mediated dilation after forearm ischemia (44) and work from our laboratory 
148
Body mass index and waist and hip circumferences were measured by anthropometry 149 as previously described (42). Arterial blood pressure and heart rate were measured over the 150 brachial artery during rest in a supine position using a semi-automated device (Dynamap XL,
151
Johnson & Johnson, Raritan, NJ).
152
Fasting plasma glucose was measured by enzymatic methods (Roche Diagnostic 
170
Angiotensin II (EDTA-and bestastin-treated plasma, Evaluating Data, RIA) and epinephrine
171
(EGTA and glutathione-treated serum, BioRad Laboratories, HPLC) were also measured, but
172
are not reported because the majority of samples were below detection limits.
173
Feasibility, Safety and Tolerability.
174
Subject adherence to the intervention was measured by pill count. Retention of subjects 175 and adverse events (Table 4) 
209
All vascular measures were performed >12 hours after ingesting the last dose of sodium 210 nitrite, and 4 to 24 hours after ingesting food, alcohol or caffeine or performing exercise (13, 41).
211
The same investigator [AED], who was blinded to the subject group assignment, performed all 212 data acquisition and analyses.
213
Brachial artery flow-mediated dilation was assessed using high-resolution 
224
Integrated System with imager and frame grabber (DICOM, Rosslyn, VA) and vascular ECG-
225
gating module (University of Iowa, Iowa City, IA). The coefficient of variation for baseline and 226 peak brachial diameter in our laboratory is 0.3% and 0.6%, respectively.
227
Local stiffness/elasticity at the carotid artery was measured as previously described (37).
228
Briefly, the subject's right common carotid artery maximal (i.e., end-systolic) and minimal (i.e., 
270
(Grubb's test) were replaced with the group mean. Differences amongst groups in baseline 271 subject characteristics were determined using One-Way ANOVA (p<0.05). Because this study 272 was designed to determine dosage and sample size for a larger clinical trial, significance was 273 set at p<0.10 for group differences (38). Sodium nitrite treatments were compared with placebo 274 using a mixed-model ANOVA (within factor, time; between factor, treatment group), with 275 contrast set to changes observed in placebo controls. In the case of a significant time x 276 treatment interaction, paired samples t-tests were performed (p<0.05).
277
After metabolomics data were filtered using MPP software (Agilent), small molecules not 278 present in at least 50% of any one group at baseline or Week 10 were excluded to reduce the 279 probability of false discovery, resulting in 3,063 detected small molecules for subsequent 
286
To assess whether baseline metabolomic signatures predict responsiveness to nitrite, 287 baseline log 2 transformed concentrations of all 3,063 molecules were tested with independent 288 linear regression models within each dosage group. Only metabolites that were significantly 289 associated with responsiveness to nitrite and did not show an interaction with dosage level (80 290 or 160 mg/d) were included. Metabolites were subsequently grouped by class using the HMDB 291 database to determine which metabolic pathways were most involved in our analysis. A subject 292 was designated "responsive to the intervention" if they exhibited a 1% improvement from compliance and a 15% improvement in β-stiffness index measures, changes shown to be 295 predictive of mortality or CVD events (16, 43).
296
Results
297
The average age of subjects was 62±1 years (range 50-77). Subjects were healthy and 298 there were no significant differences amongst groups for clinical characteristics at baseline 299 (Tables 1 and 2 ). Anthropometrics, brachial artery blood pressure, fasting blood lipids, glucose 300 and insulin remained unchanged by the intervention. Circulating analytes, including C-reactive 301 protein and endothelin-1, did not significantly change (Table 3) .
302
303
Of the 87 subjects assessed for eligibility, 34 subjects were randomized (39% enrollment 304 rate; Figure 1 ). Subjects were non-Hispanic Caucasian (84%), non-Hispanic Black/African (6%) 305 or Hispanic (10%). With only two subjects dropping out, there was a 94% completion rate for 306 the study. Subject adherence to the intervention was favorable, with 71% not missing taking 307 any capsules. Of the nine subjects who missed taking a capsule, four subjects missed one, 308 three subjects missed two and two subjects missed taking three capsules during the 10-week 309 intervention. Acquisition of data was successful for brachial artery flow-mediated dilation (97% 310 analyzable), brachial artery shear rate (94% analyzable), arterial stiffness measures (94-97% 311 analyzable) and blood analytes (71-100% analyzable).
312
No severe adverse events occurred ( Table 6 ).
334
Metabolomics.
335
To determine whether alterations in the metabolome are associated with changes in 
346
To determine the ability of the plasma metabolome to predict an individual's response to 347 nitrite supplementation, baseline metabolomic profiles were compared with changes in vascular 348 function after sodium nitrite supplementation (summary shown in Table 8 
360
Discussion
361
The primary objectives of this study were to determine our ability to recruit, retain and 362 successfully collect and analyze data in this population, and to determine the tolerability, 
374
Interest in sodium nitrite as a treatment for CVD was rekindled in recent years after 375 chronic oral supplementation was shown to protect the heart from ischemia-reperfusion injury in 
438
The information derived from this novel technique will help to determine the metabolomic 439 pathways of focus for future studies and may help predict individuals who will respond favorably 440 to treatment with sodium nitrite.
441
Limitations of the current study include the diverse nature of the plasma metabolome, 
